- Download 117
- File Size 361.87 KB
- File Count 2
- Create Date January 9, 2023
- Last Updated January 9, 2023
Special Authority: Empagliflozin and Semaglutide (inj)
Pharmacare now considers SGLT2 and GLP1 (injectable) products as 2nd line diabetes drugs - after Metformin. The attached eFORMS are specific to these products. Note that approval for a DPP4 product (a separate eFORM needed) cancels approval for either of these and vice versa.
There are two versions - one with a wet signature only (Stan Hurwitz), and one with signature stamp (John Yap) as the default and a wet signature as a back-up option.
|Ozempic-SA.zip - wet signature only||Download|
|SA_Empagliflozin_Semaglutide_V1_Jan8_2023-1.zip - signature stamp default; wet signature option available||Download|